BACKGROUND: There is a need to better understand the rate of cognitive and motor decline of Dementia with Lewy bodies (DLB) and Parkinson's disease Dementia (PDD). OBJECTIVES: To compare the rate of cognitive and motor decline in patients with DLB and PDD from the E-DLB Consortium and the Parkinson's Incidence Cohorts Collaboration (PICC) Cohorts. METHODS: The annual change in MMSE and MDS-UPDRS part III was estimated using linear mixed regression models in patients with at least one follow-up (DLB n = 837 and PDD n = 157). RESULTS: When adjusting for confounders, we found no difference in the annual change in MMSE between DLB and PDD (-1.8 [95% CI -2.3, -1.3] vs. -1.9 [95% CI -2.6, -1.2] [P = 0.74]). MDS-UPDRS part III showed nearly identical annual changes (DLB 4.8 [95% CI 2.1, 7.5]) (PDD 4.8 [95% CI 2.7, 6.9], [P = 0.98]). CONCLUSIONS: DLB and PDD showed similar rates of cognitive and motor decline. This is relevant for future clinical trial designs.

Ace Alzheimer Center Barcelona Universitat Internacional de Catalunya Barcelona Spain

Centre for Age Related Medicine Stavanger University Hospital Stavanger Norway

Department Neuroscience Research Institute Germans Trias i Pujol Badalona Spain

Department of Chemistry Bioscience and Environmental Engineering University of Stavanger Stavanger Norway

Department of Clinical Neurosciences University of Cambridge Cambridge England

Department of Clinical Science Neurosciences Umeå University Umeå Sweden

Department of Human Neurosciences Sapienza University of Rome Rome Italy

Department of Medicine and Aging Sciences University Gd'Annunzio of Chieti Pescara Chieti Italy

Department of Neurology and Neurological Sciences Stanford University School of Medicine Stanford California USA

Department of Neurology County Clinic Hospital Faculty of Medicine Transilvania University Brasov Romania

Department of Neurology Haukeland University Hospital Bergen Norway

Department of Neurology Medical University of Lublin Lublin Poland

Department of Neurology Stavanger University Hospital Stavanger Norway

Department of Old Age Psychiatry Institute of Psychiatry Psychology and Neuroscience King's College London London UK

Department of Psychiatry University of Cambridge School of Clinical Medicine Cambridge UK

Department of Quality and Health Technology Faculty of Health Sciences University of Stavanger Stavanger Norway

Grupos de investigación INFERIR and PRECEC Section of Biostatistics Universidad del Valle Santiago de Cali Colombia

Institute of Applied Health Sciences University of Aberdeen Aberdeen UK

Institute of Applied Health Sciences University of Aberdeen Polwarth Building Aberdeen UK

Memory Clinic Department of Neurology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic

Memory Resource and Research Centre Geriatrics Day Hospital Geriatrics Department University Hospital of Strasbourg Strasbourg Cedex France

Neurology Unit Department of Clinical and Experimental Sciences University of Brescia Brescia Italy

Sant Pau Memory Unit Department of Neurology IIB Sant Pau Hospital de Sant Pau Universitat Autònoma de Barcelona Barcelona Spain

The Norwegian Centre for Movement Disorders Stavanger University Hospital Stavanger Norway

The University of Sydney Camperdown Australia

Translational and Clinical Research Institute Newcastle University Tyne UK

Université de Paris Cognitive Neurology Center APHP Lariboisière Fernand Widal Hospital Paris France

Zobrazit více v PubMed

Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17(3):137–145. PubMed

Hansen D, Ling H, Lashley T, et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia. Neuropathol Appl Neurobiol 2021;47(1):143–156. PubMed

Gonzalez MC, Ashton NJ, Gomes BF, et al. Association of plasma p‐tau181 and p‐tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol 2022;79(1):32–37. PubMed PMC

van Steenoven I, Aarsland D, Weintraub D, et al. Cerebrospinal fluid Alzheimer's disease biomarkers across the Spectrum of Lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis 2016;54(1):287–295. PubMed PMC

Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2020;94(20):e2076–e2087. PubMed PMC

Fields JA. Cognitive and neuropsychiatric features in Parkinson's and Lewy body dementias. Arch Clin Neuropsychol 2017;32(7):786–801. PubMed

Takemoto M, Sato K, Hatanaka N, Yamashita T, Ohta Y, Hishikawa N, Abe K. Different clinical and neuroimaging characteristics in early stage Parkinson's disease with dementia and dementia with Lewy bodies. J Alzheimers Dis 2016;52(1):205–211. PubMed PMC

Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord 2006;21(3):337–342. PubMed

Park KW, Kim HS, Cheon S‐M, Cha J‐K, Kim S‐H, Kim JW. Dementia with Lewy bodies versus Alzheimer's disease and Parkinson's disease dementia: a comparison of cognitive profiles. J. Clin. Neurol. 2011;7(1):19–24. PubMed PMC

Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel‐Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1215–1220. PubMed PMC

Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77(5):585–589. PubMed PMC

Matar E, White SR, Taylor JP, et al. Progression of clinical features in Lewy body dementia can be detected over 6 months. Neurology 2021;97(10):e1031–e1040. PubMed PMC

Biundo R, Weis L, Bostantjopoulou S, et al. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1‐year follow‐up study. J Neural Transm (Vienna) 2016;123(4):431–438. PubMed PMC

Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurol 2009;8(7):613–618. PubMed

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89(1):88–100. PubMed PMC

Oppedal K, Borda MG, Ferreira D, Westman E, Aarsland D, European DLBC. European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative. Neurodegener Dis Manag 2019;9(5):247–250. PubMed

University of Aberdeen King's College A . Parkinson's Incidence Cohorts Collaboration (PICC); https://www.abdn.ac.uk/iahs/research/chronic-disease/picc-2071.php.

Diagnostic and statistical manual of mental disorders . DSM‐IV (Text Revision). Washington, DC: American Psychiatric Association; 2000.

Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22(12):1689–1707. quiz 1837. PubMed

Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE‐PD study. Neurology 2014;82(4):308–316. PubMed PMC

Linder J, Stenlund H, Forsgren L. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population‐based study. Mov Disord 2010;25(3):341–348. PubMed

Alves G, Müller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009;80(8):851–857. PubMed

Breen DP, Evans JR, Farrell K, Brayne C, Barker RA. Determinants of delayed diagnosis in Parkinson's disease. J Neurol 2013;260(8):1978–1981. PubMed

Caslake R, Taylor K, Scott N, et al. Age‐, gender‐, and socioeconomic status‐specific incidence of Parkinson's disease and parkinsonism in Northeast Scotland: the PINE study. Parkinsonism Relat Disord 2013;19(5):515–521. PubMed

Szwedo AA, Dalen I, Pedersen KF, et al. GBA and APOE impact cognitive decline in Parkinson's disease: a 10‐year population‐based study. Mov Disord 2022;37(5):1016–1027. PubMed PMC

Folstein MF, Folstein SE, McHugh PR. "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–198. PubMed

Fahn SER. UPDRS program members Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park: Macmillanm Healthcare Information; 1987:153–163.

Hentz JG, Mehta SH, Shill HA, Driver‐Dunckley E, Beach TG, Adler CH. Simplified conversion method for unified Parkinson's disease rating scale motor examinations. Mov Disord 2015;30(14):1967–1970. PubMed PMC

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649–2653. PubMed

Postuma RB, Berg D, Stern M, et al. Abolishing the 1‐year rule: how much evidence will be enough? Mov Disord 2016;31(11):1623–1627. PubMed

Fereshtehnejad SM, Lökk J, Wimo A, Eriksdotter M. No significant difference in cognitive decline and mortality between Parkinson's disease dementia and dementia with Lewy bodies: naturalistic longitudinal data from the Swedish dementia registry. J Parkinsons Dis 2018;8(4):553–561. PubMed

Kramberger MG, Auestad B, Garcia‐Ptacek S, et al. Long‐term cognitive decline in dementia with Lewy bodies in a large multicenter International Cohort. J Alzheimers Dis 2017;57(3):787–795. PubMed PMC

Petrova M, Mehrabian‐Spasova S, Aarsland D, Raycheva M, Traykov L. Clinical and neuropsychological differences between mild Parkinson's disease dementia and dementia with Lewy bodies. Dement Geriatr Cogn Dis Extra 2015;5(2):212–220. PubMed PMC

Keezer MR, Wolfson C, Postuma RB. Age, gender, comorbidity, and the MDS‐UPDRS: results from a population‐based study. Neuroepidemiology 2016;46(3):222–227. PubMed

Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in DLB and PD